{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:01:25Z","timestamp":1781719285337,"version":"3.54.5"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI20\/P1450"],"award-info":[{"award-number":["PI20\/P1450"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["60379"],"award-info":[{"award-number":["60379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["60386"],"award-info":[{"award-number":["60386"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the role of previous antibiotic therapy in the risk of recurrence after a Clostridioides difficile infection (CDI) treated with vancomycin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Multicentre observational study. Patients with a CDI episode achieving clinical cure with oral vancomycin and followed up 8\u2005weeks were included. Previous antibiotic exposure up to 90\u2005days was collected. Multivariate analysis of predictors of recurrence adjusted by the propensity score (PS) of being previously treated with each non-CDI antibiotic was performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred and forty-one patients were included; 216 (90%) had received systemic antibiotics. Fifty-three patients (22%) had a CDI recurrence. Rates of recurrence were lower in those treated with piperacillin\/tazobactam in the last month when compared with those not receiving piperacillin\/tazobactam [3 (7%) versus 50 (25%); P\u200a=\u200a0.01], whereas higher rates were seen in those treated with cephalosporins in the last month [26\/87 (30%) versus 27\/154 (17%); P\u200a=\u200a0.03]. In multivariate analysis controlled by the inverse probability of treatment weighting by PS, receiving \u22655\u2005days of piperacillin\/tazobactam in the last month as the last antibiotic regimen prior to CDI was independently associated with a lower risk of recurrence [adjusted OR (AOR) 0.13; 95% CI: 0.06\u20130.29; P\u200a&amp;lt;\u200a0.0001] whereas exposure for \u22655\u2005days to cephalosporins (versus piperacillin\/tazobactam) was associated with an increased risk (AOR 10.9; 95% CI: 4.4\u201327.1; P\u200a&amp;lt;\u200a0.0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Recent use of piperacillin\/tazobactam might be associated with a lower risk of CDI recurrence, while recent use of cephalosporins might promote an increased risk. These findings should be considered when treating hospitalized patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlad033","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T18:29:35Z","timestamp":1679596175000},"source":"Crossref","is-referenced-by-count":4,"title":["Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of <i>Clostridioides difficile<\/i> infection treated with vancomycin"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-8942","authenticated-orcid":false,"given":"Nicol\u00e1s","family":"Merchante","sequence":"first","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla , Avenida de Bellavista s\/n, 41014, Sevilla , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Herrero","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla , Avenida de Bellavista s\/n, 41014, Sevilla , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Valverde-Fredet","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla , Avenida de Bellavista s\/n, 41014, Sevilla , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Rodr\u00edguez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla , Avenida de Bellavista s\/n, 41014, Sevilla , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-5807","authenticated-orcid":false,"given":"H\u00e9ctor","family":"Pinargote","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas, Hospital General Universitario Dr. Balmis, Instituto de Investigaci\u00f3n Biom\u00e9dica de Alicante (ISABIAL) , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J","family":"Mart\u00ednez-Marcos","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosa, Hospital Universitario Juan Ramo\u0301n Jime\u0301nez , Huelva , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Gil-Anguita","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Marina Baixa , Villajoyosa , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Garc\u00eda-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Servico de Medicina Interna, Hospital Vega Baja , Orihuela , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Tasias Pitarch","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas, Hospital Universitario y Polite\u0301cnico La Fe , Valencia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Abril L\u00f3pez De Medrano","sequence":"additional","affiliation":[{"name":"Servicio de Enfermedades Infecciosas, Consorcio Hospitalario General Universitario de Valencia , Valencia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Nicol\u00e1s","family":"Navarrete Lorite","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Hospital Universitario Virgen Macarena. Departamento de Medicina, Universidad de Sevilla. Instituto de Biomedicina de Sevilla (IBiS)\/CSIC , Sevilla , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"G\u00f3mez-Ayerbe","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Unidad de Enfermedades Infecciosas, Hospital Cli\u0301nico Universitario Virgen de la Victoria , Ma\u0301laga , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Le\u00f3n","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla , Avenida de Bellavista s\/n, 41014, Sevilla , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Gonz\u00e1lez-De La Aleja","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas, Hospital General Universitario Dr. Balmis, Instituto de Investigaci\u00f3n Biom\u00e9dica de Alicante (ISABIAL) , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ruiz Castillo","sequence":"additional","affiliation":[{"name":"Servicio Microbiolog\u00eda, Hospital Universitario Juan Ramo\u0301n Jime\u0301nez , Huelva , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I","family":"Aller","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla , Avenida de Bellavista s\/n, 41014, Sevilla , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-5739","authenticated-orcid":false,"given":"Juan Carlos","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Servicio Microbiolog\u00eda, Hospital General Universitario de Alicante, Instituto de Investigaci\u00f3n Biom\u00e9dica de Alicante (ISABIAL) , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ternero Fonseca","sequence":"additional","affiliation":[{"name":"Servicio de Aparato Digestivo, Hospital Universitario Juan Ramo\u0301n Jime\u0301nez , Huelva , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan E","family":"Corzo","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla , Avenida de Bellavista s\/n, 41014, Sevilla , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Naranjo P\u00e9rez","sequence":"additional","affiliation":[{"name":"Servicio de Aparato Digestivo, Hospital Universitario Juan Ramo\u0301n Jime\u0301nez , Huelva , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Trigo-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla , Avenida de Bellavista s\/n, 41014, Sevilla , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Merino","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas, Hospital General Universitario Dr. Balmis, Instituto de Investigaci\u00f3n Biom\u00e9dica de Alicante (ISABIAL) , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"2023111202093559400_dlad033-B1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"key":"2023111202093559400_dlad033-B2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(14)70991-0","article-title":"Underdiagnosis of Clostridium difficile across Europe: the European, multicenter, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalized patients with diarrhea (EUCLID)","volume":"14","author":"Davies","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2023111202093559400_dlad033-B3","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMra1403772","article-title":"Clostridium difficile infection","volume":"372","author":"Longo","year":"2015","journal-title":"N Engl J Med"},{"key":"2023111202093559400_dlad033-B4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/cid\/cir301","article-title":"Cumulative antibiotic exposure over time and the risk of Clostridium difficile infection","volume":"53","author":"Stevens","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023111202093559400_dlad033-B5","first-page":"1193","article-title":"Cumulative and temporal associations between antimicrobial prescribing and community-associated Clostridium difficile infection: population-based case-control study using administrative data","volume":"72","author":"Kavanagh","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023111202093559400_dlad033-B6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/dkt477","article-title":"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis","volume":"69","author":"Slimings","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2023111202093559400_dlad033-B7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/cid\/ciaa124","article-title":"Antibiotic prescribing choices and their comparative C. difficile infection risks: a longitudinal case-cohort study","volume":"72","author":"Brown","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023111202093559400_dlad033-B8","doi-asserted-by":"crossref","first-page":"e01269-19","DOI":"10.1128\/AAC.02169-19","article-title":"Antibiotic exposure and risk for hospital-associated Clostridioides difficile infection","volume":"64","author":"Webb","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023111202093559400_dlad033-B9","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1001\/jamainternmed.2016.6193","article-title":"Receipt of antibiotics in hospitalized patients and risk of Clostridium difficile infection in subsequent patients who occupy the same bed","volume":"176","author":"Freedberg","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2023111202093559400_dlad033-B10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1473-3099(16)30397-8","article-title":"Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis","volume":"17","author":"Lawes","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023111202093559400_dlad033-B11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cid\/ciz169","article-title":"Association between antibiotic use and hospital-onset Clostridioides difficile infection in US acute care hospitals, 2006-2012: an ecologic analysis","volume":"70","author":"Kazakova","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023111202093559400_dlad033-B12","first-page":"1067","article-title":"Associations of facility-level antibiotic use and hospital-onset Clostridioides difficile infection in US acute-care hospitals, 2012\u20132018","volume":"7","author":"Kazakova","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023111202093559400_dlad033-B13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"2023111202093559400_dlad033-B14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for the prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Eng J Med"},{"key":"2023111202093559400_dlad033-B15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(17)30751-X","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial","volume":"18","author":"Guery","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023111202093559400_dlad033-B16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/cid\/civ958","article-title":"Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection","volume":"62","author":"Sheitoyan-Pesant","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"2023111202093559400_dlad033-B17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin","volume":"55","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023111202093559400_dlad033-B18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4321\/S1135-57272013000100004","article-title":"Cost of Clostridium difficile associated diarrhea in Spain","volume":"1","author":"Asensio","year":"2013","journal-title":"Rev Esp Salud Publ"},{"key":"2023111202093559400_dlad033-B19","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.cmi.2021.04.004","article-title":"Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection","volume":"27","author":"Chen","year":"2021","journal-title":"Clin Microb Infect"},{"key":"2023111202093559400_dlad033-B20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/cid\/cir404","article-title":"Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections","volume":"53","author":"Mullane","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023111202093559400_dlad033-B21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/ajhp\/zxz032","article-title":"Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings","volume":"76","author":"Appaneal","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"2023111202093559400_dlad033-B22","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S1473-3099(22)00274-2","article-title":"How can patients with Clostridioides difficile infection on concomitant antibiotic treatment be best managed?","volume":"22","author":"Fitzpatrick","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023111202093559400_dlad033-B23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cmi.2021.09.026","article-title":"Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review","volume":"28","author":"van Rossen","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"2023111202093559400_dlad033-B24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2023111202093559400_dlad033-B25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023111202093559400_dlad033-B26","author":"ECDC","year":"2019"},{"issue":"Suppl 4","key":"2023111202093559400_dlad033-B27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmi.2016.03.010","article-title":"European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection","volume":"22","author":"Crobach","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2023111202093559400_dlad033-B28","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1093\/cid\/ciaa1902","article-title":"Risk of acute kidney injury and Clostridioides difficile infection with piperacillin\/tazobactam, cefepime and meropenem with or without vancomycin","volume":"73","author":"Lee","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023111202093559400_dlad033-B29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13756-020-00815-5","article-title":"Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis","volume":"9","author":"Sholeh","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023111202093559400_dlad033-B30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12879-016-1514-2","article-title":"Do piperacillin\/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?","volume":"16","author":"Kundrapu","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2023111202093559400_dlad033-B31","doi-asserted-by":"crossref","first-page":"e0161200","DOI":"10.1371\/journal.pone.0161200","article-title":"Association of fidaxomicin with C. difficile spores: effects of persistence on subsequent spore recovery, outgrowth and toxin production","volume":"11","author":"Chilton","year":"2016","journal-title":"PLoS One"},{"key":"2023111202093559400_dlad033-B32","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41586-022-05438-x","article-title":"Enterococci enhance Clostridioides difficile pathogenesis","volume":"611","author":"Smith","year":"2022","journal-title":"Nature"},{"key":"2023111202093559400_dlad033-B33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jinf.2019.10.008","article-title":"The effect of antibiotics on the composition of the intestinal microbiota - a systematic review","volume":"79","author":"Zimmermann","year":"2019","journal-title":"J Infect"},{"key":"2023111202093559400_dlad033-B34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2022.09.013","article-title":"Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?","volume":"124","author":"Krutova","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2023111202093559400_dlad033-B35","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkr508","article-title":"Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics","volume":"67","author":"Hensgens","year":"2012","journal-title":"J Antimicrob Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/2\/dlad033\/53277387\/dlad033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/2\/dlad033\/53277387\/dlad033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T02:10:00Z","timestamp":1699755000000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlad033\/7084812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlad033","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,3,2]]},"article-number":"dlad033"}}